Market Overview:
The biosimilar market in Europe reached a value of US$ 5,341 Million in 2020. The European biosimilar market represents the most mature in the world and continues to rally momentum. This market is expected to grow robustly in the next five years, as a number blockbuster biologics are scheduled to lose patent protection in Europe. Looking forward, IMARC Group expects the biosimilar market in Europe to exhibit strong growth during the next five years.
Biosimilars are biotherapeutic products which are similar to already licensed reference biologics, in terms of quality, safety and efficiency. Biosimilar manufacturers wait till the patent of the reference product expires and then seek approval from the regulatory authorities in order to produce their biosimilar versions. These manufacturers use the state-of-the-art technology for comparing the characteristics, such as purity, chemical identity and bioactivity, of the proposed biosimilar to its reference product. In 2005, a science-based regulatory framework was established in the European Union (EU) for ensuring the production of high-quality biosimilars. Later in 2006, the European Medicines Agency (EMA) approved the first biosimilar medicine, Omnitrope. Since then, a number of biosimilars belonging to various therapeutic classes have been approved in Europe.
Biosimilars Market in Europe: Drivers
- Biosimilars are less expensive than their branded counterparts as they do not require extensive research and testing which saves both money and time; thereby lowering the costs. Moreover, they also have short marketing times as launching a biosimilar does not require extensive marketing as the safety and efficacy profile of their branded counterparts have already been established.
- Several blockbuster biologics are expected to lose their patent protection over the next 5 to 10 years. This expiration of patents and other intellectual property rights is expected to create huge opportunities for biosimilar manufacturers.
- The European population is ageing with around one fifth of the total EU population above 65 years of age. There has resulted in a significant increase in the burden of lifestyle diseases in the region. The prevalence of diseases such as diabetes, autoimmune diseases, oncology, etc. has been increasing rapidly in Europe. This is also expected to propel the market growth during the next few years.
- As a result of rising healthcare costs, governments across a number of European countries have formulated policies incentivising physicians, pharmacists and patients in favour of biosimilars over branded biologics.
Market Summary:
Breakup by Country:
- Italy
- Germany
- United Kingdom
- France
- Spain
- Others
Country-wise, the market has been segmented into Italy, Germany, United Kingdom, France, Spain and Others.
Breakup by Molecule
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
The report has analysed the market on the basis of molecule. The market has been segmented into Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, etc.
Breakup by Indication
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
The report has also analysed the market on the basis of indication. Other major indications include oncology, autoimmune diseases, blood disorders, growth deficiency, diabetes, etc.
Breakup by Manufacturing Type
- In-house Manufacturing
- Contract Manufacturing
On the basis of manufacturing type, the report has segmented the market into in-house manufacturing and contract manufacturing.
Some of the leading players operating in the European biosimilars market include:
- Novartis
- Pfizer
- Teva
- Celltrion
- Samsung Bioepis
- Amgen
- Apotex
- Ratiopharm
- Mylan
- Merck Sharp & Dohme
- Eli Lilly
- Accord Healthcare Ltd
- Boehringer Ingelheim
- Hexal Ag
- Stada Arzneimittel Ag
This report provides a deep insight into the European biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the European biosimilars market in any manner.
Key Questions Answered in This Report:
The Europe Biosimilar market size was valued at US$ 5,341 Million in 2020.
According to the estimates by IMARC Group, the Europe biosimilar market is expected to witness a CAGR of 22.1% from 2021 to 2026.
In Europe, the market growth has been driven by the relatively lower prices of biosimilars as compared to branded counterparts, since they do not require extensive investments for research and development (R&D).
The rapid patent expiration of a number of blockbuster biologics, coupled with an increase in the awareness about the efficiency and safety of biosimilars, represent some of the major trends in the Europe biosimilar market.
Sudden outbreak of the COVID-19 pandemic had led to the implementation of stringent lockdown regulations in the nation resulting in the postponement of numerous clinical trials pertaining to biosimilars.
On the basis of the molecule, the market has been bifurcated into infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, follitropin alfa, and adalimumab. Currently, infliximab holds the majority of the total market share.
On the basis of the indication, the market has been divided into auto-immune diseases, oncology, diabetes, blood disorders, growth deficiency, and female infertility. Among these, auto-immune diseases represent the largest segment.
On the basis of the manufacturing type, the market has been segmented into in-house manufacturing and contract manufacturing. Among these, in-house manufacturing exhibits a clear dominance in the market.
Region-wise, the market has been classified into Italy, Germany, United Kingdom, France, Spain, and others, where Italy dominates Europe biosimilar market.
The key companies in the Europe biosimilar market are Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion, Inc., Merck & Co., Inc. (Merck Sharp & Dohme), Samsung Bioepis Co. Ltd., Eli Lilly and Company, Accord Healthcare Ltd., Amgen, Inc., C.H. Boehringer Sohn AG & Ko. KG, Hexal AG, Apotex, Inc., Stada Arzneimittel AG, Ratiopharm GmbH and Mylan N.V.
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Europe Biosimilars Market – Introduction
4.1 Overview
4.2 WHO and EMA Terminology on Biosimilars
4.3 Biosimilars and Generics
4.4 Biosimilars and Branded Biological Products
5 Europe Biosimilars Market
5.1 Market Overview
5.2 Historical and Current Market Trends
5.3 Impact of COVID-19
5.4 Market Breakup by Country
5.5 Market Breakup by Molecule
5.6 Market Breakup by Indication
5.7 Market Breakup by Manufacturing Type
5.8 Patent Landscape
5.9 Market Forecast
6 Market Breakup by Country
6.1 Italy
6.1.1 Market Performance
6.1.2 Key Players and Biosimilars
6.1.3 Market Forecast
6.2 Germany
6.2.1 Market Performance
6.2.2 Key Players and Biosimilars
6.2.3 Market Forecast
6.3 France
6.3.1 Market Performance
6.3.2 Key Players and Biosimilars
6.3.3 Market Forecast
6.4 United Kingdom
6.4.1 Market Performance
6.4.2 Key Players and Biosimilars
6.4.3 Market Forecast
6.5 Spain
6.5.1 Market Performance
6.5.2 Key Players and Biosimilars
6.5.3 Market Forecast
6.6 Rest of Europe
6.6.1 Market Performance
6.6.2 Market Forecast
7 Market Breakup by Molecule
7.1 Infliximab
7.2 Insulin Glargine
7.3 Epoetin Alfa
7.4 Etanercept
7.5 Filgrastim
7.6 Somatropin
7.7 Rituximab
7.8 Follitropin Alfa
7.9 Adalimumab
8 Market Breakup by Manufacturing Type
8.1 In-house Manufacturing
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Contract Manufacturing
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Indication
9.1 Auto-Immune Diseases
9.2 Blood Disorder
9.3 Diabetes
9.4 Oncology
9.5 Growth Deficiency
9.6 Female Infertility
10 European Biosimilar Market: SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 European Biosimilar Market: Value Chain Analysis
11.1 Characterizing the Existing Innovator Drug
11.2 Research and Development
11.2.1 Characterization of Biosimilars
11.2.2 Developing a Unique Cell Line
11.3 Product Development
11.3.1 Pre-Testing
11.3.2 Intermediary Clinical Testing (PK/PD)
11.3.3 Confirmatory Clinical Phase-III
11.4 Final Product Formulation
11.5 Marketing and Distribution
12 Porter’s Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
13.1 Key Price Indicators
13.2 Price Trends
14 Requirements for Setting Up a Generic Drug Manufacturing Plant
14.1 Manufacturing Process
14.2 Raw Material Requirements
14.3 Raw Material Pictures
14.4 Land and Construction Requirements
14.5 Machinery and Infrastructure Requirements
14.6 Machinery Pictures
14.7 Plant Layout
14.8 Packaging Requirements
14.9 Utility Requirements
14.10 Manpower Requirements
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Novartis
15.3.2 Pfizer
15.3.3 Teva
15.3.4 Celltrion
15.3.5 Merck Sharp & Dohme
15.3.6 Samsung Bioepis
15.3.7 Eli Lilly
15.3.8 Accord Healthcare Ltd.
15.3.9 Amgen
15.3.10 Boehringer Ingelheim
15.3.11 Hexal Ag
15.3.12 Apotex
15.3.13 Stada Arzneimittel Ag
15.3.14 Ratiopharm
15.3.15 Mylan
List of Figures
Figure 1: Europe: Biosimilar Market: Sales Value (in Million US$), 2015-2020
Figure 2: Europe: Biosimilar Market: Breakup by Molecule (in %), 2020
Figure 3: Europe: Biosimilar Market: Breakup by Manufacturer (in %), 2020
Figure 4: Europe: Biosimilar Market: Breakup by Indication (in %), 2020
Figure 5: Europe: Biosimilar Market: Breakup by Country (in %), 2020
Figure 6: Europe: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 7: Italy: Biosimilar Market: Sales Value (in Million US$), 2015-2020
Figure 8: Italy: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 9: Germany: Biosimilar Market: Sales Value (in Million US$), 2015-2020
Figure 10: Germany: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: France: Biosimilar Market: Sales Value (in Million US$), 2015-2020
Figure 12: France: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: United Kingdom: Biosimilar Market: Sales Value (in Million US$), 2015-2020
Figure 14: United Kingdom: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Spain: Biosimilar Market: Sales Value (in Million US$), 2015-2020
Figure 16: Spain: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Rest of Europe: Biosimilar Market: Sales Value (in Million US$), 2015-2020
Figure 18: Rest of Europe: Biosimilar Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Europe: Rituximab Biosimilar Market: Sales Value (in Million US$), 2017
Figure 20: Europe: Infliximab Biosimilar Market: Sales Value (in Million US$), 2015 - 2017
Figure 21: Europe: Insulin Glargine Biosimilar Market: Sales Value (in Million US$), 2016 & 2017
Figure 22: Europe: Epoetin Alfa Biosimilar Market: Sales Value (in Million US$), 2014 - 2017
Figure 23: Europe: Filgrastim Biosimilar Market: Sales Value (in Million US$), 2014 - 2017
Figure 24: Europe: Somatropin Biosimilar Market: Sales Value (in Million US$), 2014 - 2017
Figure 25: Europe: Etanercept Biosimilar Market: Sales Value (in Million US$), 2016 & 2017
Figure 26: Europe: Follitropin Alfa Biosimilar Market: Sales Value (in Million US$), 2015 - 2017
Figure 27: Europe: Adalimumab Biosimilar Market: Sales Value (in Million US$), 2018
Figure 28: Europe: Biosimilar Market (In-House Manufacturing): Sales Value (in Million US$), 2015-2020
Figure 29: Europe: Biosimilar Market Forecast (In-House Manufacturing): Sales Value (in Million US$), 2021-2026
Figure 30: Europe: Biosimilar Market (Contract Manufacturing): Sales Value (in Million US$), 2015 & 2020
Figure 31: Europe: Biosimilar Market Forecast (Contract Manufacturing): Sales Value (in Million US$), 2021-2026
Figure 32: Europe: Biosimilar Market (Autoimmune Diseases): Sales Value (in Million US$), 2015 & 2020
Figure 33: Europe: Biosimilar Market Forecast (Autoimmune Diseases): Sales Value (in Million US$), 2021-2026
Figure 34: Europe: Biosimilar Market (Blood Disorders): Sales Value (in Million US$), 2015 & 2020
Figure 35: Europe: Biosimilar Market Forecast (Blood Disorders): Sales Value (in Million US$), 2021-2026
Figure 36: Europe: Biosimilar Market (Diabetes): Sales Value (in Million US$), 2015 & 2020
Figure 37: Europe: Biosimilar Market Forecast (Diabetes): Sales Value (in Million US$), 2021-2026
Figure 38: Europe: Biosimilar Market (Oncology): Sales Value (in Million US$), 2015 & 2020
Figure 39: Europe: Biosimilar Market Forecast (Oncology): Sales Value (in Million US$), 2021-2026
Figure 40: Europe: Biosimilar Market (Growth Deficiency): Sales Value (in Million US$), 2015 & 2020
Figure 41: Europe: Biosimilar Market Forecast (Growth Deficiency): Sales Value (in Million US$), 2021-2026
Figure 42: Europe: Biosimilar Market (Female Infertility): Sales Value (in Million US$), 2015 & 2020
Figure 43: Europe: Biosimilar Market Forecast (Female Infertility): Sales Value (in Million US$), 2021-2026
Figure 44: Europe: Biosimilar Industry: SWOT Analysis
Figure 45: Europe: Biosimilar Industry: Value Chain Analysis
Figure 46: Europe: Biosimilar Industry: Porter’s Five Forces Analysis
Figure 47: Biosimilar Manufacturing: Detailed Process Flow
List of Tables
Table 1: Europe: Sales and Patent Expiry of Blockbuster Biological Drugs (in Million US$)
Table 2: Biosimilar vs. Innovators Drug Development
Table 3: Biosimilar vs. Biologics Manufacturing
Table 4: Europe: Biosimilar Market: Key Industry Highlights, 2020 and 2026
Table 5: Europe: Biosimilar Market: Patent Landscape
Table 6: Europe: Biosimilar Market: Price Comparison Between Biosimilar and Originator Drugs
Table 7: Europe: Biosimilar Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 8: Europe: Biosimilar Market: Key Players and Biosimilars
Table 9: Italy: Biosimilar Market: Key Players and Biosimilars
Table 10: Germany: Biosimilar Market: Key Players and Biosimilars
Table 11: France: Biosimilar Market: Key Players and Biosimilars
Table 12: United Kingdom: Biosimilar Market: Key Players and Biosimilars
Table 13: Spain: Biosimilar Market: Key Players and Biosimilars
Table 14: Europe: Rituximab: Brand & Biosimilar Market Overview
Table 15: Europe: Infliximab: Brand & Biosimilar Market Overview
Table 16: Europe: Insulin Glargine: Brand & Biosimilar Market Overview
Table 17: Europe: Epoetin Alfa: Brand & Biosimilar Market Overview
Table 18: Europe: Filgrastim: Brand & Biosimilar Market Overview
Table 19: Europe: Somatropin: Brand & Biosimilar Market Overview
Table 20: Europe: Etanercept: Brand & Biosimilar Market Overview
Table 21: Europe: Follitropin Alfa: Brand & Biosimilar Market Overview
Table 22: Europe: Biosimilar Market Forecast: Breakup by Manufacturing Type (in Million US$), 2021-2026
Table 23: Europe: Biosimilar Market Forecast: Breakup by Indication (in Million US$), 2021-2026
Table 24: Biosimilar Manufacturing Plant: Raw Material Requirements
Table 25: Biosimilar Manufacturing Plant: Land and Construction Requirements
Table 26: Biosimilar Manufacturing Plant: Machinery Requirements
Table 27: Biosimilar Manufacturing Plant: Manpower Requirements
Table 28: Europe: Biosimilar Market: Competitive Structure
Table 29: Europe: Biosimilar Market: Key Players